|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in studying interactions between aerosols and monsoon in China显示文摘Scientific issues relevant to interactions between aerosols and the Asian monsoon climate were discussed and evaluated at the 33 rd 'Forum of Science and Technology Frontiers' sponsored by the Department of Earth Sciences at the Chinese Academy of Sciences. Major results are summarized in this paper. The East Asian monsoon directly affects aerosol transport and provides a favorable background circulation for the occurrence and development of persistent fog-haze weather. Spatial features of aerosol transport and distribution are also influenced by the East Asian monsoon on seasonal, inter-annual, and decadal scales. High moisture levels in monsoon regions also affect aerosol optical and radiative properties. Observation analyses indicate that cloud physical properties and precipitation are significantly affected by aerosols in China with aerosols likely suppressing local light and moderate rainfall, and intensifying heavy rainfall in southeast coastal regions. However, the detailed mechanisms behind this pattern still need further exploration. The decadal variation in the East Asian monsoon strongly affects aerosol concentrations and their spatial patterns. The weakening monsoon circulation in recent decades has likely helped to increase regional aerosol concentrations. The substantial increase in Chinese air pollutants has likely decreased the temperature difference between land and sea, which favors intensification of the weakening monsoon circulation. Constructive suggestions regarding future studies on aerosols and monsoons were proposed in this forum and key uncertain issues were also discussed. | WU GuoXiong LI ZhanQing FU CongBin ZHANG XiaoYe ZHANG RenYi ZHANG RenHe ZHOU TianJun LI JianPing LI JianDong ZHOU DeGang WU Liang ZHOU LianTong HE Bian HUANG RongHui | 2016 | Science China Earth Sciences2016，59，1： | 16 |
| 2 | Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19:a phase 1 clinical trial显示文摘No effective drug treatments are available for coronavirus disease 2019(COVID-19).Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage,death,or long-term functional disability in survivors require clinical evaluation.We performed a parallel assigned controlled,non-randomized,phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells(UC-MSCs)infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.The study enrolled 18 hospitalized patients with COVID-19(n=9 for each group).The treatment group received three cycles of intravenous infusion of UC-MSCs(3×107 cells per infusion)on days 0,3,and 6.Both groups received standard COVID-treatment regimens.Adverse events,duration of clinical symptoms,laboratory parameters,length of hospitalization,serial chest computed tomography(CT)images,the PaO2/FiO2 ratio,dynamics of cytokines,and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed.No serious UC-MSCs infusion-associated adverse events were observed.Two patients receiving UC-MSCs developed transient facial flushing and fever,and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion.Mechanical ventilation was required in one patient in the treatment group compared with four in the control group.All patients recovered and were discharged.Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated.Phase 2/3 randomized,controlled,double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19. | Fanping Meng Ruonan Xu Siyu Wang Zhe Xu Chao Zhang Yuanyuan Li Tao Yang Lei Shi Junliang Fu Tianjun Jiang Lei Huang Peng Zhao Xin Yuan Xing Fan Ji-Yuan Zhang Jinwen Song Dawei Zhang Yanmei Jiao Limin Liu Chunbao Zhou Markus Maeurer Alimuddin Zumla Ming Shi Fu-Sheng Wang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 16 |
| 3 | Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial显示文摘Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We conducted a randomized,controlled,open-label multicenter trial among COVID-19 patients.The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone.The cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were observed.Thirty-three patients were randomized to the tocilizumab group,and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events occurred.More mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative.For patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome. | Dongsheng Wang Binqing Fu Zhen Peng Dongliang Yang Mingfeng Han Min Li Yun Yang Tianjun Yang Liangye Sun Wei Li Wei Shi Xin Yao Yan Ma Fei Xu Xiaojing Wang Jun Chen Daqing Xia Yubei Sun Lin Dong Jumei Wang Xiaoyu Zhu Min Zhang Yonggang Zhou Aijun Pan Xiaowen Hu Xiaodong Mei Haiming Wei Xiaoling Xu | 2021 | Frontiers of Medicine2021，15，3： | 2 |
| 4 | Mechanistic study of copper-catalyzed intramolecular ortho-C-H activation/carbon-nitrogen and carbon-oxygen cyclizations显示文摘Intramolecular ortho-C-H activation and C-N/C-O cyclizations of phenyl amidines and amides have recently been achieved under Cu catalysis. These reactions provide important examples of Cu-catalyzed functionalization of inert C-H bonds, but their mechanisms remain poorly understood. In the present study the several possible mechanisms including electrophilic aromatic substitution, concerted metalation-deprotonation (CMD), Friedel-Crafts mechanism, radical mechanism, and protoncoupled electron transfer have been theoretically examined. Cu(Ⅱ)-assisted CMD mechanism is found to be the most feasible for both C-O and C-N cyclizations. This mechanism includes three steps, i.e. CMD with Cu(Ⅱ), oxidation of the Cu(Ⅱ) intermediate, and reductive elimination from Cu(Ⅲ). Our calculations show that Cu(Ⅱ) mediates the C-H activation through an six-membered ring CMD transition state similar to that proposed for many Pd-catalyzed C-H activation reactions. It is also interesting to find that the rate-limiting steps are different for C-N and C-O cyclizations: for the former it is concerted metalation-deprotonation with Cu(Ⅱ), whereas for the latter it is reductive elimination from Cu(Ⅲ). The above conclusions are consistent with the experimental kinetic isotope effects (1.0 and 2.1 for C-O and C-N cyclizations, respectively), substituent effects, and the reactions under O2 -free conditions. | TANG ShiYa GONG TianJun FU Yao | 2013 | Science China Chemistry2013，56，5： | 2 |
| 5 | Development of a roll-bonded UNS N08825 alloy clad pipeline steel in Baosteel显示文摘In this study,a roll-bonded UNS N088225 alloy clad pipeline steel was investigated and developed in Baosteel. Based on the requirements of a number of potential projects,we performed a series of strict evaluations including mechanical and corrosion tests. The results show the mechanical properties and corrosion resistance of this clad steel to be excellent and to meet the requirements of all the design parameters. | LIANG Xiaojun MA Tianjun FU Yanhong JIAO Sihai DING Jianhua YUAN Xiangqian WANG Baosen ZHANG Qingfeng | 2017 | Baosteel Technical Research2017，11，1： | 1 |
| 6 | A focused crawler for Dark Web forums显示文摘 | Tianjun Fu Ahmed Abbasi Hsinchun Chen | 2010 | JASIST2010，6，6： | 1 |
| 7 | A hybrid approach to Web forum interactional coherence analysis 显示文摘 | Fu Tianjun AbbasiA Chen H | 2008 | Journal of the American Society for Information Science and Technology2008，59，8： | 1 |
| 8 | Clinical Epidemiology,Illness Profiles,and the Implication of COVID-19 Before and After the Nationwide Omicron Outbreak During the Winter of 2022显示文摘China.In this study,we aimed to investigate the clinical characteristics and outcomes of patients with coronavirus disease 2019(COVID-19)in the Beijing region.Methods:In this retrospective study,we enrolled inpatients admitted for COVID-19 in the Fifth Medical Center of Chinese PLA General Hospital in Beijing between November 10,2022,and January 30,2023.Demographic and clinical features and treatment outcomeswere comprehensively analyzed.We used logistic regression and linear regression analyses to explore the risk factors associated with disease severity and time of nucleic acid conversion,respectively.Results:A total of 1010 hospitalized patients with COVID-19 were enrolled.The median age was 43.0 years(interquartile range,28.0–63.0),and patients aged<60 years and≥60 years comprised 71.2%and 28.8%of total included patients,respectively.The clinical classification of mild(74.6%,753/1010),moderate(21.0%,212/1010),severe(2.7%,27/1010),and unidentified(1.8%,18/1010)was separately recorded;1005 patients were discharged,and 5 patients died in the hospital.The outbreak of the emerging epidemic witnessed an evident increase in the proportion of moderate(42.9%vs.16.4%)and severe(10.3%vs.1.1%)cases after December 7,2022.Patients with a moderate/severe classification had higher levels of procalcitonin,IL-6,serum ferritin,C-reactive protein,lactic dehydrogenase,serum urea nitrogen,and D-dimer and lower counts of CD4+T,CD8+T,and B cells(all P<0.001).Multivariable regression analysis revealed that increased odds of disease severity were associated with the following factors:age≥60 years,IL-6>7 pg/mL,lactic dehydrogenase level>245 U/L,cough,and fever at admission.Age≥80 years and chronic lung diseasewere independent risk factors in the nonmild group in elderly patients.In addition,the duration for nucleic acid to turn negativewas approximately 5.0 d(interquartile range,3.0–7.0).Prolonged time of nucleic acid conversion was associated with age≥60 years,serum urea nitrogen level>8.2 mmol/L,neutrophil count>7×10^(9)/L,and the presence of a chronic lung disease or carcinoma.Finally,unvaccinated patients accounted for 37.3%of enrolled patients;children and the elder people accounted for approximately half of that.The univariable analysis found that booster doses reduced disease severity and shortened the time of nucleic acid conversion in elderly patients.Conclusions:The outbreak ofOmicron rapidly increased the number of patientswith COVID-19 in Beijing.In elderly patients,booster doses may reduce disease severity and shorten the time of nucleic acid conversion.Healthcare systems should be optimized before an emerging epidemic outbreak. | Yuming Guo Zhe Xu Wen-Xin Wang Cheng Zhen Jinhua Hu Jinsong Mu Chengcheng Ji Xin Yuan Ruonan Xu Lei Huang Lei Shi Fanping Meng Junliang Fu Shuangnan Zhou Siyu Wang Fengyi Li Bo Tu Dawei Zhang Huihuang Huang Yufeng Mao Wen Xu Chao Zhang Xiuying Mu Jun Zhao Bo Jin Haibin Su Yinying Lu Yongqian Cheng Dong Ji Shaoli You Jinghui Dong Changchun Liu Mengmeng Zhang Yuanyuan Li Tianjun Jiang Yonggang Li Fu-Sheng Wang | 2023 | Infectious Diseases & Immunity2023，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员